NCT01788072View on ClinicalTrials.gov

INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

October 31, 2017

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Intranasal Oxytocin

24 IU taken twice daily (BID), in the morning and at noon/early afternoon

DRUG

Placebo

24 IU taken twice daily (BID), in the morning and at noon/early afternoon

Trial Locations (2)

L8S 4K1

St. Joseph's Healthcare Hamilton, Hamilton

M4G 1R8

Holland Bloorview Kids Rehabilitation Hospital, Toronto

All Listed Sponsors
collaborator

McMaster University

OTHER

collaborator

Unity Health Toronto

OTHER

lead

Holland Bloorview Kids Rehabilitation Hospital

OTHER

NCT01788072 - INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter